

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/525,797	03/15/2000		Athanasius A Anagnostou	5218-39B	9917
20792	7590	05/03/2006		EXAMINER	
MYERS B	IGEL SIE	BLEY & SAJOVEC	UNGAR, SUSAN NMN		
PO BOX 37	'428				
RALEIGH, NC 27627		27		ART UNIT	PAPER NUMBER
				1642	

DATE MAILED: 05/03/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action

Application No.	Applicant(s)		
09/525,797	ANAGNOSTOU ET AL.		
Examiner	Art Unit		
Susan Ungar	1642		

Before the Filing of an Appeal Brief --The MAILING DATE of this communication appears on the cover sheet with the correspondence address --THE REPLY FILED 28 February 2006 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. 1. X The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods: The period for reply expires ____ months from the mailing date of the final rejection. a) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. Examiner Note: If box 1 is checked, check either box (a) or (b), ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL 2. The Notice of Appeal was filed on ____ A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a). **AMENDMENTS** 3. The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will not be entered because (a) They raise new issues that would require further consideration and/or search (see NOTE below): (b) They raise the issue of new matter (see NOTE below); (c) They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or (d) They present additional claims without canceling a corresponding number of finally rejected claims. NOTE: See Continuation Sheet. (See 37 CFR 1.116 and 41.33(a)). 4. The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324). 5. Applicant's reply has overcome the following rejection(s): 6. Newly proposed or amended claim(s) _____ would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s). 7. Tor purposes of appeal, the proposed amendment(s): a) will not be entered, or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended. The status of the claim(s) is (or will be) as follows: Claim(s) allowed: none. Claim(s) objected to: none. Claim(s) rejected: 12-15,19-21,23-26 and 31-35. Claim(s) withdrawn from consideration: none. AFFIDAVIT OR OTHER EVIDENCE 8. The affidavit or other evidence filed after a final action, but before or on the date of filing a Notice of Appeal will not be entered because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and was not earlier presented. See 37 CFR 1.116(e). 9. The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will not be entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1). 10. The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached. REQUEST FOR RECONSIDERATION/OTHER 11. The request for reconsideration has been considered but does NOT place the application in condition for allowance because: See Continuation Sheet. 12. Note the attached Information Disclosure Statement(s). (PTO/SB/08 or PTO-1449) Paper No(s). 13. Other: _____. Primary Examiner

Art Unit: 1642

Continuation of 3. NOTE: New issues raised are drawn to the recitation of administration of EPO prior to the initial administration of a chemotherapeutic recited in claims 12 and 21 as well as drawn to chemotherapeutics not previously examined, that is carboplatin and mitomycin recited in claim 15. Further, the recitation of "prior to initial administration" appears to be new matter since the only support suggested by Applicant for the newly added limitation is an invitro study of the effect of EPO administered prior to CIS which is not commensurate in scope with the claimed invention. Further, a review of the specification did not reveal support for the newly added limitation drawn to carboplatin.

Continuation of 11. does NOT place the application in condition for allowance because: the request for consideration and the amendment have not been entered for the reasons set forth above. Further, the arguments presented drawn to the rejections under 35 USC 102 and 103 are drawn to the subject matter of the newly added limitations, which have not been entered and therefore are moot. If the Amendment had been entered, claims 12, 19-21, 23-26, 31-35 rejection under 35 USC 112 first paragraph would have been retained for the reasons previously set forth in the action mailed 1/27/06.

Applicant argues that the Sigounas Declaration demonstrated that a reduction in tumor mass resulted from the sequential administration of EPO and mitomycin and despite the fact that the difference was not statistically significant, the data show that EPO can modulate tumor response to chemotherapy. The argument has been considered but has not been found persuasive since the data clearly demonstrates that lack of statictical significance of the finding and given this lack, no one of ordinary skill would believe it more likely than not that the data demonstrates that EPO can modulate tumor response to chemotherapy. It is noted that Applicant's arguments drawn to "prior to initial administration" and to carboplatin and mitomycin are moot since the amendment has not been entered.